Hang Quach

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.

Ajay K Nooka, Katja Weisel, Niels Wcj van de Donk, David Routledge, Paula Rodriguez Otero, Kevin Song, Hang Quach, Natalie Callander, Monique C Minnema, Suzanne Trudel, Nicola A Jackson, Christoph M Ahlers, Ellie Im, Shinta Cheng, L Smith, Nahi Hareth, Geraldine Ferron-Brady, Maria Brouch, Rocio Montes de Oca, Sofia Paul, et al.

Journal article  |  2021  |  Future Oncology

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapse..

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis

Thomas G Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michele Cavo, Philippe Moreau, Meletios Dimopoulos, Kwee Yong, Christina Tekle, Meredith C Foster, Yvonne Barnes, Marie-Laure Risse, Joseph Mikhael

Journal article  |  2021  |  Transplantation and Cellular Therapy

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Philippe Moreau, Shaji K Kumar, Jesus San Miguel, Faith Davies, Elena Zamagni, Nizar Bahlis, Heinz Ludwig, Joseph Mikhael, Evangelos Terpos, Fredrik Schjesvold, Thomas Martin, Kwee Yong, Brian GM Durie, Thierry Facon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels van de Donk, Sagar Lonial, Michele Cavo, et al.

Journal article  |  2021  |  The Lancet Oncology

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relap..

Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.

Chhay Lim, Priyadarshini Sinha, Simon J Harrison, Hang Quach, Monica A Slavin, Benjamin W Teh

Journal article  |  2021  |  Clinical Lymphoma Myeloma & Leukemia

INTRODUCTION: Treatment for multiple myeloma (MM) has continued to evolve with second generation immunomodulatory drugs (IMiDs), p..

Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma

Marcel Doerflinger, Alexandra L Garnham, Saskia Freytag, Simon J Harrison, H Miles Prince, Hang Quach, Monica A Slavin, Marc Pellegrini, Benjamin W Teh

Journal article  |  2021  |  Clinical & Translational Immunology

Objectives: Patients with multiple myeloma (MM) are at increased risk for infection. Clinical assessment of infection risk is incr..

The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)

Krystal Bergin, Cameron Wellard, Elizabeth Moore, Zoe McQuilten, Hilary Blacklock, Simon J Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Erica Wood, Andrew Spencer

Journal article  |  2021  |  Clinical Lymphoma Myeloma & Leukemia

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

Meletios A Dimopoulos, Ivan Spicka, Hang Quach, Albert Oriol, Roman Hajek, Mamta Garg, Meral Beksac, Sara Bringhen, Eirini Katodritou, Wee-Joo Chng, Xavier Leleu, Shinsuke Iida, Maria-Victoria Mateos, Gareth Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial

Journal article  |  2020  |  Journal of Clinical Oncology

PURPOSE: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not..

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Nizar J Bahlis, Roman Hajek, Reuben Benjamin, Tuphan K Dolai, Dinesh K Sinha, Christopher P Venner, Mamta Garg, Mercedes Gironella, Artur Jurczyszyn, et al.

Journal article  |  2020  |  The Lancet

BACKGROUND: Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a p..

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Maria Mateos, Sundar Jagannath, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Irina Kryachok, Maria Gavriatopoulou, Meletios A Dimopoulos, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim A Doronin, Ganna Usenko, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P Venner, Mamta Garg, Don A Stevens, et al.

Journal article  |  2020  |  Blood

Introduction Selinexor is a first-in-class, oral, potent selective inhibitor of nuclear export (SINE) which blocks ..

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay Nooka, Keith Stockerl-Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, Maria-Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A Smith, Jacqueline Davidge, Rocio Montes de Oca, Geraldine Ferron-Brady, Anne Yeakey, Mala Talekar, Brandon E Kremer, et al.

Conference Proceedings  |  2020  |  Blood

Introduction: Single-agent belamaf (GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, demonstrated deep ..